Application of signal pathway signal inhibitor or protein synthesis inhibitor or madecassic acid in preparation of drug for treating osteoporosis

A technology of madecassoside and osteoporosis, which is used in drug combinations, bone diseases, pharmaceutical formulations, etc., can solve the problems of intolerance in elderly patients, large side effects, and large gastrointestinal side effects and kidney toxicity, etc. The effect of good application prospects

Inactive Publication Date: 2019-09-10
WENZHOU MEDICAL UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, bisphosphonates have relatively large gastrointestinal side effects and nephrotoxicity, which are difficult for elderly patients to tolerate; long-term use of calcitonin can increase the risk of potential cancer; estrogen is mainly used for postmenopausal women with osteoporosis , but its side effects are relatively large, which will increase the risk of endometrial cancer, breast cancer and cardiovascular disease in women

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of signal pathway signal inhibitor or protein synthesis inhibitor or madecassic acid in preparation of drug for treating osteoporosis
  • Application of signal pathway signal inhibitor or protein synthesis inhibitor or madecassic acid in preparation of drug for treating osteoporosis
  • Application of signal pathway signal inhibitor or protein synthesis inhibitor or madecassic acid in preparation of drug for treating osteoporosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0024] In order to illustrate the content of the present invention more clearly, specific examples are used to illustrate the following, and the specific examples do not limit the scope of the content of the present invention.

[0025] Materials and methods

[0026] Material

[0027] primary antibody

[0028] NFATc1, rabbit monoclonal IgG Santa Cruz Corporation Integrin β3, rabbit monoclonal IgG Santa Cruz Corporation Cathepsin K, mouse monoclonal IgG Santa Cruz Corporation V-ATPase-d2, rabbit monoclonal IgG Santa Cruz Corporation IκB-α, rabbit monoclonal IgG Santa Cruz Corporation pERK1 / 2, mouse monoclonal IgG Santa Cruz Corporation ERK1 / 2, rabbit monoclonal IgG Santa Cruz Corporation β-actin, mouse monoclonal IgG Santa Cruz Corporation c-Fos, rabbit monoclonal IgG Cell Signaling TechnologyCompany pJNK1 / 2, rabbit monoclonal IgG Cell Signaling TechnologyCompany JNK1 / 2, mouse monoclonal IgG Cell S...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

An application of a signal pathway signal inhibitor or a protein synthesis inhibitor or a madecassic acid in preparation of a drug for treating osteoporosis is disclosed. The madecassic acid inhibitsan expression of key protein-NFATc1 required for effect performance of osteoclasts through NF-[kappa]B, calcium / calmodulin-dependent kinase and MAPK three signal transduction pathways, and RANKL-induced osteoclast generation is ultimately inhibited. The application first describes and demonstrates that the madecassic acid has a satisfactory therapeutic effect on osteoporosis caused by estrogen deficiency, suggests that a natural compound madecassic acid extracted from Chinese herbal medicine has good application prospects in prevention and treatment of the osteoporosis, and provides a new option and a drug development idea for the treatment of the osteoporosis.

Description

technical field [0001] The invention relates to the technical field of osteoporosis drugs, in particular to the application of a signal pathway signal inhibitor or protein synthesis inhibitor or madecassoside in the preparation of drugs for treating osteoporosis. Background technique [0002] Osteoporosis is a systemic metabolic bone disease characterized by decreased bone mass, degeneration of bone tissue microstructure, and increased bone fragility. It is more common in postmenopausal women and elderly men. At present, my country has more than 210 million people over the age of 60 (about 15.5% of the total population), and nearly 140 million people over the age of 65 (about 10.1% of the total population). It is the country with the largest absolute number of elderly people in the world. According to With the forecast of population structure and the extension of life expectancy, the number of elderly people will further increase in the future. As a bone disease related to a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/7024A61P19/10A61K36/23
CPCA61K31/7024A61K36/23A61K45/00A61P19/10
Inventor 许可郑绿珍王清清徐家科
Owner WENZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap